Ngam Advisors LP Increased Its Regeneron Pharmaceuticals (REGN) Stake by $6.80 Million

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) LogoInvestors sentiment decreased to 1.14 in Q3 2018. Its down 0.05, from 1.19 in 2018Q2. It turned negative, as 39 investors sold REGN shares while 173 reduced holdings. 89 funds opened positions while 153 raised stakes. 70.41 million shares or 0.23% more from 70.25 million shares in 2018Q2 were reported. New York-based Hudson Bay LP has invested 0.07% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Zeke Advsrs Ltd Liability Co stated it has 0.14% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Franklin Resource accumulated 652,885 shares. Advisor Partners Lc accumulated 0.05% or 957 shares. Northern Capital Mgmt Limited Liability Company owns 0.23% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 2,440 shares. First Tru Advsr LP invested 0.22% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Robeco Institutional Asset Mgmt Bv, Netherlands-based fund reported 5,564 shares. 712 are held by Perigon Wealth Mngmt Ltd Liability. Hightower Advsr Ltd Com invested 0.08% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Schwab Charles Invest Inc has invested 0.08% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). 21,791 were reported by Nuveen Asset Management Ltd Liability Com. Stonebridge Capital Incorporated stated it has 0.31% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Old Natl Comml Bank In holds 0.14% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 6,955 shares. Principal Gru reported 116,631 shares stake. New Amsterdam Prns Lc Ny reported 934 shares or 0.1% of all its holdings.

Since June 20, 2018, it had 0 insider purchases, and 8 sales for $99.12 million activity. GOLDSTEIN JOSEPH L had sold 4,000 shares worth $1.46 million. 2,000 shares valued at $784,524 were sold by BROWN MICHAEL S on Thursday, September 27. 104,552 shares valued at $42.52M were sold by Sanofi on Thursday, September 6.

Ngam Advisors Lp increased its stake in Regeneron Pharmaceuticals (REGN) by 8.88% based on its latest 2018Q3 regulatory filing with the SEC. Ngam Advisors Lp bought 16,826 shares as the company’s stock declined 4.42% with the market. The institutional investor held 206,250 shares of the health care company at the end of 2018Q3, valued at $83.33M, up from 189,424 at the end of the previous reported quarter. Ngam Advisors Lp who had been investing in Regeneron Pharmaceuticals for a number of months, seems to be bullish on the $40.87B market cap company. The stock increased 0.60% or $2.24 during the last trading session, reaching $377.96. About 594,077 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 1.07% since December 12, 2017 and is uptrending. It has outperformed by 1.07% the S&P500.

Ngam Advisors Lp, which manages about $16.78B and $11.36 billion US Long portfolio, decreased its stake in Equity Residential (NYSE:EQR) by 67,702 shares to 125,815 shares, valued at $8.34M in 2018Q3, according to the filing. It also reduced its holding in Mastercard Incorporated (NYSE:MA) by 17,112 shares in the quarter, leaving it with 161,699 shares, and cut its stake in Borgwarner Inc (NYSE:BWA).

More notable recent Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news were published by: which released: “Nasdaq 100 Movers: JD, REGN – Nasdaq” on June 19, 2018, also with their article: “Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma – PRNewswire” published on December 01, 2018, published: “Galapagos’ Osteoarthritis Candidate Gets Fast Track Status – Nasdaq” on November 28, 2018. More interesting news about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were released by: and their article: “Congo approves clinical trials for Ebola treatments – Nasdaq” published on November 24, 2018 as well as‘s news article titled: “Ziopharm: Elucidating The Regeneron Partnership For Glioblastoma – Seeking Alpha” with publication date: November 14, 2018.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Ratings Coverage

Among 7 analysts covering Regeneron (NASDAQ:REGN), 2 have Buy rating, 1 Sell and 4 Hold. Therefore 29% are positive. Regeneron had 10 analyst reports since June 27, 2018 according to SRatingsIntel. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Buy” rating by Argus Research on Monday, July 16. The firm has “Equal-Weight” rating by Morgan Stanley given on Thursday, October 11. The company was maintained on Friday, August 3 by Canaccord Genuity. Morgan Stanley maintained Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) rating on Friday, August 3. Morgan Stanley has “Equal-Weight” rating and $409 target. As per Thursday, October 11, the company rating was maintained by Canaccord Genuity. The firm has “Equal-Weight” rating by Morgan Stanley given on Friday, July 13. As per Friday, August 3, the company rating was downgraded by Robert W. Baird. The company was maintained on Monday, August 6 by Barclays Capital. The firm has “Buy” rating given on Wednesday, June 27 by Oppenheimer.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.